Guardant Health to Appeal Federal District Court Judgment

Guardant Health stock tumbled Monday after losing a patent battle against privately held TwinStrand Biosciences.

Guardant Health must pay TwinStrand Biosciences and the University of Washington over $245 million after a court finalized a patent dispute.